

Issued: 6 June 2012, India

GlaxoSmithKline Pharmaceuticals Limited Introduces Metered Dose Inhaler with dose counter

Mumbai: GlaxoSmithKline Pharmaceuticals Limited today announced the launch of an enhanced version of a Metered Dose Inhaler (MDI) with dose counter, for the first time in India. This inhaler has an innovative dose counter that keeps track of number of doses left. This helps the patients to take the right number of drug doses. The inhaler also has a locking system which prevents drug wastage when the inhaler is not in use.

Commenting about the launch, Dr. Hasit Joshipura, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, “We are excited about the launch of this inhaler with dose counter. This enhancement is yet another step in our endeavour to help patients take the appropriate dosage of their medicine as prescribed by their physician.”

The technology has been introduced in Seretide[®] Evohaler[®]. The inhaler is indicated for management of asthma and COPD in patients above 4 years of age.

About GlaxoSmithKline

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For company information, visit GlaxoSmithKline PLC at www.gsk.com OR GlaxoSmithKline Pharmaceuticals Limited at www.gsk-india.com.

For More Details Contact: